Aprea Therapeutics has appointed Eyal Attar senior vice president and chief medical officer. Attar joins Aprea from Agios Pharmaceuticals, where he was senior medical director and IDH hematology medical lead. Aprea, which splits its operations between Boston and Stockholm, Sweden, is developing therapies that target the tumor suppressor protein p53. The company’s most advanced drug candidate, APR-246, is in Phase 3 testing as a treatment for myelodysplastic syndromes.
Author: Frank Vinluan
Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times.
View all posts by Frank Vinluan
